Stock Events

Stock Events

Adagene 

$3.58
13
-$0.11-2.98% Friday 20:00
+$0.00+0%Friday 23:30After hours

Statistics

Day High
3.59
Day Low
3.56
52W High
4.85
52W Low
1.3
Volume
3,586
Avg. Volume
-
Mkt Cap
240.37M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

25JulExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q2 2024
-1.23
-0.82
-0.41
0
Expected EPS
N/A
Actual EPS
-0.26

Financials

-229.55%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
7.67MRevenue
-17.61MNet Income

Analyst Ratings

10.00Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADAG. It's not an investment recommendation.
Clover Health Investments
3
CLOV
Atara Biotherapeutics
3
ATRA
Immutep Limited
3
IMMP
Tesla
2
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals competes in the monoclonal antibody space, similar to Adagene's focus on antibody engineering and innovation.
AMGEN
AMGN
Mkt Cap236.38B
Amgen is a biotech giant that develops innovative therapeutics, including antibody-based treatments that could compete with Adagene's pipeline.
Merck
MRK
Mkt Cap370.89B
Merck & Co. has a strong presence in the oncology market, directly competing with Adagene's cancer-focused antibody therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb offers a range of cancer treatments, including antibody therapies that rival Adagene's products.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech division, is a leader in biotechnology and antibody-based drugs, competing in the same space as Adagene.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a diverse portfolio of drugs, including cancer therapies that could compete with Adagene's antibody-based treatments.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company is involved in the development of monoclonal antibodies for various diseases, posing competition to Adagene's offerings.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is known for its innovative treatments in oncology and other areas, competing with Adagene's therapeutic approaches.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong pipeline in oncology, including antibody therapies that could compete with Adagene's products.
Novartis
NVS
Mkt Cap304.1B
Novartis AG focuses on innovative healthcare solutions, including monoclonal antibodies for cancer treatment, directly competing with Adagene.

About

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Show more...
CEO
Peter Luo
Employees
128
Country
Cayman Islands
ISIN
US0053291078
WKN
000A2QN45

Listings

STU
DE
978.STU
MU
DE
978.MU
F
DE
978.F
XNAS
US
ADAG

0 Comments

Share your thoughts

FAQ

What is Adagene stock price today?▼
The current price of ADAG is $3.58 USD — it has decreased by -2.98% in the past 24 hours. Watch Adagene stock price performance more closely on the chart.
What is Adagene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Adagene stocks are traded under the ticker ADAG.
Is Adagene stock price growing?▼
ADAG stock has risen by +1.99% compared to the previous week, the month change is a -12.9% fall, over the last year Adagene has showed a +62.73% increase.
What is Adagene market cap?▼
Today Adagene has the market capitalization of 240.37M
What were Adagene earnings last quarter?▼
ADAG earnings for the last quarter are -0.26 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adagene revenue for the last year?▼
Adagene revenue for the last year amounts to 7.67M USD.
What is Adagene net income for the last year?▼
ADAG net income for the last year is -17.61M USD.
How many employees does Adagene have?▼
As of September 07, 2026, the company has 128 employees.
In which sector is Adagene located?▼
Adagene operates in the Health & Wellness sector.
When did Adagene complete a stock split?▼
Adagene has not had any recent stock splits.
Where is Adagene headquartered?▼
Adagene is headquartered in Suzhou, Cayman Islands.